UK +44 (0) 203 929 0534 | US +1 (917) 297-6587

Cross-Portfolio Strategy

What is the future of digital therapeutics, and what threats and opportunities does that present us?

Digital therapeutics represent an entirely new therapeutics modality in its infancy, with potential for decentralised cost-effective care at scale.

Our client, a global pharmaceutical and medical technology company, sought to better understand the threat and opportunity for their pipeline and portfolio. This required understanding future potential indications, and what the business model would look like.

We created a comprehensive competitive and technology landscape, stratified by strict criteria to separate out adjunctive digital therapies from truly stand-alone digital therapeutics. Interviews with KOLs allowed us to project the future of the industry, creating scenarios for our client to illustrate their strategic options.

< Previous Case Study

Next Case Study >

Home                  Expertise                   Our Team                   Join us                    Contact us

Brand & Website design by GeoMedia           Privacy Policy

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

Home                  Expertise                   Our Team                   Join Us                    Contact Us

Home                  Expertise                   Our Team
Join Us                    Contact Us

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

Brand & Website design by GeoMedia          Privacy Policy